Purpose: The mechanism of action and pharmacokinetics of sirolimus when used as part of a drug-eluting stent (DES) and the efficacy and cost of using DESs versus bare-metal stents are discussed.
Hosted on MSN9mon
Biodexa gains license for polyposis asset as stock more than doublesFyarro consists of sirolimus albumin-bound particles, and is administered as an intravenous (IV) infusion twice a month. The drug won US Food and Drug Administration (FDA) approval in 2021 for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback